Latest Conference Articles

Zongertinib shows significant benefits in managing symptoms and improving quality of life for patients with HER2-mutated non-small cell lung cancer.

Sander Kersten, PhD, discusses the distinct roles of ANGPTL3 and ANGPTL4 in lipid metabolism, their interactions with key enzymes, the therapeutic potential of targeting these pathways in lipid-lowering strategies, and important considerations for pharmacists counseling patients on emerging ANGPTL-targeted therapies.

Katherine H. Saunders, MD, DABOM, explores the role of pharmacists in supporting long-term weight management with GLP-1 therapies, including strategies for counseling on lifestyle interventions, managing adverse effects, and ensuring patients receive individualized, evidence-based care.

Two abstracts from the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that pretreatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing genotype-guided dosing strategies.

Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.

Elranatamab shows promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients, highlighting its potential as a treatment option.

Daratumumab combined with VRd significantly improved outcomes in transplant-ineligible/transplant deferred patients with newly diagnosed multiple myeloma.

Epcoritamab shows impressive long-term remission rates in relapsed large B-cell lymphoma, highlighting its potential as a key treatment option.

Alice H. Lichtenstein, DSc, emphasizes the importance of whole-food dietary patterns over macronutrient percentages for improving lipid profiles and cardiovascular health.

Pre-treatment DPYD genotyping significantly reduces hospitalizations and costs for patients with cancer, enhancing safety and efficiency in oncology care.

Grace Nguyen, PharmD, BCPS, provides real-world experiences with DPYD genotype-guided fluoropyrimidine dosing, highlighting how pharmacist-led interventions and tailored dose adjustments can help mitigate toxicity risks and optimize treatment in variant carriers.

The data from the phase 3 SEQUOIA study are to be presented at the 2025 ASCO Annual Meeting.

Imetelstat shows promise in treating myelofibrosis, enhancing survival, and modifying disease biology in patients resistant to JAK inhibitors.

Christian John Lillis reflects on key insights from the 2025 Peggy Lillis Foundation C diff Summit, highlighting the critical role of pharmacists in infectious disease care, persistent challenges in patient outcomes, and the need for renewed investment in public health infrastructure and policy.

Christian John Lillis discusses the 2025 Peggy Lillis Foundation C diff Summit, emphasizing the enduring need for community-building among survivors, the importance of sustained public health advocacy, and the growing urgency to defend federal health agencies amid political and institutional uncertainty.

At the 2025 SPPCP Virtual Conference, Carolyn Hall, PharmD, BCPS, and Maria Felton Lowry, PharmD, BCPS, BCGP, presented a comprehensive and practical framework for pharmacy professionals to build effective, adaptable mentorship relationships.

In a session at the 2025 Virtual Conference on Pain and Palliative Care, Isabella Zerfas, PharmD, and Abbey Galligan, PharmD, BCPS, explore effective pain management strategies for opioid use disorder (OUD) and complex persistent opioid dependence.

Experts emphasize the importance of tailored vaccination strategies for pneumococcal based on individual risk factors.

RSV vaccination for older adults requires understanding risk factors, using empathetic communication strategies, and proactively identifying eligible patients through careful review of medical histories and care transitions.

Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, received a leadership award at the 2025 HOPA Annual Meeting.

Logan Schneider, MD, highlights the importance of integrating patient-reported outcomes into clinical trials to better capture the full therapeutic impact of low-sodium oxybate (Xywav) beyond traditional sleep metrics.

Emma Murter, PharmD, MPH, and Madison N. Irwin, PharmD, BCPS, discuss the potential role of low-dose naltrexone in managing chronic pain in palliative care, highlighting its anti-inflammatory properties, limited adverse effects, and current evidence gaps—particularly in comparison to traditional opioids and adjuvant analgesics.

Specialty pharmacy experts and key opinion leaders gathered at Asembia’s AXS25 Summit and discussed critical insights in interviews with Pharmacy Times®.

Lacy La Fever, PharmD, MS, discussed outcomes associated with different carboplatin AUC dosing strategies.

Specialty pharmacy experts discuss how emotional support, addressing patient loneliness, and peer-to-patient programs can significantly improve medication adherence and patient care.

Experts emphasized the importance of addressing regulatory and payer-side challenges to fully leverage AI's potential in pharmacy settings.

Digital pharmacy solutions are revolutionizing patient care.